US equities |
SPCX $166.68 ▲+4.86% NVDA $236.67 ▲+1.16% MU $1,064.44 ▼-0.97% TSLA $377.78 ▲+1.94% MSFT $525.58 ▲+1.56% SNDK $1,711.00 ▼-0.52% INTC $117.18 ▼-1.80% META $745.62 ▲+2.41%
FinancialContent

Tiziana Life Sciences Ltd - Common Shares (NQ:TLSA)

1.115 -0.005 (-0.45%)
Delayed Quote Updated: 11:42 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tiziana Life Sciences Ltd - Common Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
EXCLUSIVE: Tiziana Life Sciences Plans To Develop Multiple Sclerosis Hopeful For Long COVID Patients ↗
Tiziana Life Sciences Ltd (NASDAQ: TLSA) plans to investigate intranasal foralumab for Long COVID. What Happened: The work is supported by foralumab's well-established role in de-activating microglia... 
Via Benzinga
News headline image
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise ↗
Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies... 
Via Benzinga
News headline image
NIO Could Bring A Pleasant Beat This Coming Quarter
Tesla's price cuts have initiated a full on war across the EV industry, however NIO has refused to follow along. This may present even more upside for the stock 
Via MarketBeat
Topics Electric Vehicles
News headline image
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Receives Sign-Off From The FDA To Proceed With Phase 2 Clinical Trial In Patients With Non-Active Secondary Progressive Multiple Sclerosis (SPMS) ↗
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) announced it has received feedback based on the U.S. Food and Drug Administration (FDA) Type C meeting minutes related to the Phase 2 clinical trial of... 
Via Benzinga
News headline image
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
FDA Provides Positive Feedback on Intranasal Foralumab Program in Patients with Non-Active SPMS 
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Highlighted in Forbes Article
Article entitled "New T Cell Antibody Treatment Improves Outcomes For Covid Patients" reviews the company's first in class foralumab, a unique Intranasal monoclonal antibody designed to treat multiple... 
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
7 Thrilling Stocks to Buy for Aggressive Investors ↗
Sometimes you need to be aggressive to unlock the best returns for your portfolio. Just be smart when looking for the best stocks to buy. 
Via InvestorPlace
News headline image
Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely"
Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely" 
Via News Direct
Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely"
Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a 2023 Clinical Outlook for clinical stage biotechnology company Tiziana Life Sciences Ltd (NASDAQ:TLSA). He gives his... 
Via TheNewswire.com
News headline image
Tesla HODLs Bitcoin — But Sticks To Dogecoin-Only Crypto Payments Policy ↗
Electric car maker Tesla Inc (NASDAQ: TLSA) continues to hold on to Bitcoin (CRYPTO: BTC) but only accepts Dogecoin (CRYPTO:  
Via Benzinga
News headline image
Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Posts Additional Clinical Improvements In Second Patient with Multiple Sclerosis ↗
 
Via Benzinga
News headline image
Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022
Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need 
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana to Participate in January Investor Meetings
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price Requirements
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Date of Annual General Meeting 2022
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >